Phospholipase C (PLC)-1, activated by p122RhoGTPase-activating protein (GAP)/deleted in liver cancer-1 (p122RhoGAP/DLC-1), contributes to the coronary spastic angina (CSA) pathogenesis. The present study aims to further investigate the p122RhoGAP/DLC-1 protein. We examined molecules assisting this protein and identified a scaffold protein-IQ motif-containing GTPase-activating protein 1 (IQGAP1). IQGAP1-C binds to the steroidogenic acute regulatory-related lipid transfer (START) domain of p122RhoGAP/DLC-1, and PLC-1 binds to IQGAP1-N, forming a complex. In fluorescence microscopy, small dots of PLC-1 created fine linear arrays like microtubules, and IQGAP1 and p122RhoGAP/DLC-1 were colocated in the cytoplasm with PLC-1. Ionomycin induced the raft recruitment of the PLC-1, IQGAP1, and p122RhoGAP/DLC-1 complex by translocation to the plasma membrane (PM), indicating the movement of this complex is along microtubules with the motor protein kinesin. Moreover, the IQGAP1 protein was elevated in skin fibroblasts obtained from patients with CSA, and it enhanced the PLC activity and peak intracellular calcium concentration in response to acetylcholine. IQGAP1, a novel stimulating protein, forms a complex with p122RhoGAP/DLC-1 and PLC-1 that moves along microtubules and enhances the PLC activity.Keywords: Phospholipase C, p122RhoGTPase-activating protein (GAP)/deleted in liver cancer-1, IQ motif-containing GTPase-activating protein 1, coronary spastic angina, acetylcholine (IP 3 ) and diacylglycerol. IP 3 mobilizes Ca 2+ from the intracellular stores and exhibits rapid contraction of the vascular smooth muscle (Korn et al., 1988), whereas diacylglycerol activates protein kinase C and triggers the sustained muscle contraction via a Ca 2+ -independent mechanism (Ito et al., 1994). Previously, we have reported the enhanced PLC activity in cultured skin fibroblasts obtained from patients with CSA and determined that a major PLC isozyme in the membrane fraction was the 1 isoform, which is more sensitive to Ca 2+ than other isozymes (Okumura et al., 2000). Furthermore, we have demonstrated the presence of a G to A mutation at nucleotide position 864 in PLC-1 in patients with CSA, accompanied by the amino acid (aa) replacement of arginine 257 to histidine (R257H), which markedly enhanced the PLC enzymatic activity in the physiological range of the intracellular free calcium concentration ([Ca 2+ ] i ) (Nakano et al., 2002). To elucidate its role in coronary spasm, we created mice that overexpressed the variant PLC-1 (R257H) under the control of the mouse -SMA promoter and illustrated that the elevated PLC-1 activity enhanced coronary vasomotility, as observed in patients with CSA (Shibutani et al., 2012).A study has demonstrated that p122RhoGTPase-activating protein (GAP)/deleted in liver cancer-1 (p122RhoGAP/DLC-1), cloned as a PLC-1-interacting protein from a rat brain expression library, exhibits a specific GTPase-activating protein (GAP) activity on Rho, augmenting the PIP 2 hydrolyzing activity of PLC-1 in vitro...